Skip to main content
Top
Published in: Tumor Biology 6/2014

01-06-2014 | Research Article

Reevaluation of survival and prognostic factors in pathologic stage I lung adenocarcinoma by the new 2009 TNM classification

Authors: Xiaohong Fan, Xueyan Zhang, Huimin Wang, Bo Jin

Published in: Tumor Biology | Issue 6/2014

Login to get access

Abstract

The incidence of lung adenocarcinoma has been increased significantly year by year. In this histologic type, complete surgical resection is commonly chosen as treatment method at the initial stages. However, the postoperative survival rate remains unsatisfactory even within the stage I. The purpose of this study is to investigate the factors related with prognosis in stage I lung adenocarcinoma after surgical resection. In this manuscript, a retrospective study was performed. Survival rates were calculated by the Kaplan-Meier method, and for multivariate analyses, Cox proportional hazards regression model was used. The results indicated that a total of 531 patients were included. Overall 5-year survival was 81.2 %. Age, sex, pathologic stage, T category, tumor size, differentiation, necrosis, visceral pleural invasion (VPI), lymphatic vessel or vascular invasion, and serum carcinoembryonic antigen (CEA) were significantly associated with 5-year overall survival of the patients with Kaplan-Meier analysis. Moreover, on multivariate analyses, seven variables were shown to be independent prognostic factors, including differentiation (hazard ratios (HR), 1.357), VPI (HR, 0.551), lymphatic vessel or vascular invasion (HR, 0.533), necrosis (HR, 1.671), age (HR, 1.519), pathological stage (HR, 4.477), and CEA (HR, 2.099). In conclusion, the most important prognostic factor is pathologic stage. Other adverse prognostic factors include differentiation, VPI, lymphatic vessel or vascular invasion, necrosis, age, and CEA.
Literature
1.
go back to reference Thanopoulou E, Kotzamanis G, Pateras IS, Ziras N, Papalambros A, Mariolis-Sapsakos T, et al. The single nucleotide polymorphism g.1548A > G (K469E) of the ICAM-1 gene is associated with worse prognosis in non-small cell lung cancer. Tumor Biol. 2012;33(5):1429–36.CrossRef Thanopoulou E, Kotzamanis G, Pateras IS, Ziras N, Papalambros A, Mariolis-Sapsakos T, et al. The single nucleotide polymorphism g.1548A > G (K469E) of the ICAM-1 gene is associated with worse prognosis in non-small cell lung cancer. Tumor Biol. 2012;33(5):1429–36.CrossRef
2.
go back to reference Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26(21):3543–51.CrossRefPubMed Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26(21):3543–51.CrossRefPubMed
3.
go back to reference Sculier JP, Chansky K, Crowley JJ, Van Meerbeeck J, Goldstraw P. International Staging Committee and Participating Institutions. The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th edition of the TNM Classification of Malignant Tumors and the proposals for the 7th edition. J Thorac Oncol. 2008;3(4):457–66.CrossRefPubMed Sculier JP, Chansky K, Crowley JJ, Van Meerbeeck J, Goldstraw P. International Staging Committee and Participating Institutions. The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th edition of the TNM Classification of Malignant Tumors and the proposals for the 7th edition. J Thorac Oncol. 2008;3(4):457–66.CrossRefPubMed
4.
go back to reference Asmis TR, Ding K, Seymour L, Shepherd FA, Leighl NB, Winton TL, et al. National Cancer Institute of Canada Clinical Trials Group. Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials. J Clin Oncol. 2008;26(1):54–9.CrossRefPubMed Asmis TR, Ding K, Seymour L, Shepherd FA, Leighl NB, Winton TL, et al. National Cancer Institute of Canada Clinical Trials Group. Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials. J Clin Oncol. 2008;26(1):54–9.CrossRefPubMed
5.
go back to reference Goldstraw P. New staging system: how does it affect our practice? J Clin Oncol. 2013;31(8):984–91.CrossRefPubMed Goldstraw P. New staging system: how does it affect our practice? J Clin Oncol. 2013;31(8):984–91.CrossRefPubMed
6.
go back to reference Sobin L, Gospodarowicz M, Wittekind C, editors. TNM classification of malignant tumors. 7th ed. Geneva: UICC International Union Against Cancer; 2009. 136–146. Sobin L, Gospodarowicz M, Wittekind C, editors. TNM classification of malignant tumors. 7th ed. Geneva: UICC International Union Against Cancer; 2009. 136–146.
7.
go back to reference Tsuboi M, Ohira T, Saji H, Miyajima K, Kajiwara N, Uchida O, et al. The present status of postoperative adjuvant chemotherapy for completely resected nonsmall cell lung cancer. Ann Thorac Cardiovasc Surg. 2007;13(2):73–7.PubMed Tsuboi M, Ohira T, Saji H, Miyajima K, Kajiwara N, Uchida O, et al. The present status of postoperative adjuvant chemotherapy for completely resected nonsmall cell lung cancer. Ann Thorac Cardiovasc Surg. 2007;13(2):73–7.PubMed
8.
go back to reference Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6(2):244–85.PubMedCentralCrossRefPubMed Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6(2):244–85.PubMedCentralCrossRefPubMed
9.
go back to reference Ebright MI, Zakowski MF, Martin J, Venkatraman ES, Miller VA, Bains MS, et al. Clinical pattern and pathologic stage but not histologic features predict outcome for bronchioloalveolar carcinoma. Ann Thorac Surg. 2002;74(5):1640–6.CrossRefPubMed Ebright MI, Zakowski MF, Martin J, Venkatraman ES, Miller VA, Bains MS, et al. Clinical pattern and pathologic stage but not histologic features predict outcome for bronchioloalveolar carcinoma. Ann Thorac Surg. 2002;74(5):1640–6.CrossRefPubMed
10.
go back to reference Chamogeorgakis T, Ieromonachos C, Georgiannakis E, Mallios D. Does lobectomy achieve better survival and recurrence rates than limited pulmonary resection for T1N0M0 non-small cell lung cancer patients? Interact Cardiovasc Thorac Surg. 2009;8(3):364–72.CrossRefPubMed Chamogeorgakis T, Ieromonachos C, Georgiannakis E, Mallios D. Does lobectomy achieve better survival and recurrence rates than limited pulmonary resection for T1N0M0 non-small cell lung cancer patients? Interact Cardiovasc Thorac Surg. 2009;8(3):364–72.CrossRefPubMed
11.
go back to reference Yoshizawa A, Motoi N, Riely GJ, Sima CS, Gerald WL, Kris MG, et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol. 2011;24(5):653–64.CrossRefPubMed Yoshizawa A, Motoi N, Riely GJ, Sima CS, Gerald WL, Kris MG, et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol. 2011;24(5):653–64.CrossRefPubMed
12.
go back to reference Urer HN, Kocaturk CI, Gunluoglu MZ, Arda N, Bedirhan MA, Fener N, et al. Relationship between lung adenocarcinoma histological subtype and patient prognosis. Ann Thorac Cardiovasc Surg 2013. [Epub ahead of print] Urer HN, Kocaturk CI, Gunluoglu MZ, Arda N, Bedirhan MA, Fener N, et al. Relationship between lung adenocarcinoma histological subtype and patient prognosis. Ann Thorac Cardiovasc Surg 2013. [Epub ahead of print]
13.
go back to reference Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, et al. International Association for the Study of Lung Cancer International Staging Committee; Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2007;2(8):706–14.CrossRefPubMed Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, et al. International Association for the Study of Lung Cancer International Staging Committee; Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2007;2(8):706–14.CrossRefPubMed
14.
go back to reference Rami-Porta R, Ball D, Crowley J, Giroux DJ, Jett J, Travis WD, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol. 2007;2(8):593–602.CrossRefPubMed Rami-Porta R, Ball D, Crowley J, Giroux DJ, Jett J, Travis WD, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol. 2007;2(8):593–602.CrossRefPubMed
15.
go back to reference Sun Z, Aubry MC, Deschamps C, Marks RS, Okuno SH, Williams BA, et al. Histologic grade is an independent prognostic factor for survival in non-small cell lung cancer: an analysis of 5018 hospital- and 712 population-based cases. J Thorac Cardiovasc Surg. 2006;131(5):1014–20.CrossRefPubMed Sun Z, Aubry MC, Deschamps C, Marks RS, Okuno SH, Williams BA, et al. Histologic grade is an independent prognostic factor for survival in non-small cell lung cancer: an analysis of 5018 hospital- and 712 population-based cases. J Thorac Cardiovasc Surg. 2006;131(5):1014–20.CrossRefPubMed
16.
go back to reference Chang YL, Lin MW, Shih JY, Wu CT, Lee YC. The significance of visceral pleural surface invasion in 32 1 cases of non-small cell lung cancers with pleural retraction. Ann Surg Oncol. 2012;19(9):3057–64.CrossRefPubMed Chang YL, Lin MW, Shih JY, Wu CT, Lee YC. The significance of visceral pleural surface invasion in 32 1 cases of non-small cell lung cancers with pleural retraction. Ann Surg Oncol. 2012;19(9):3057–64.CrossRefPubMed
17.
go back to reference Chansky K, Sculier JP, Crowley JJ, Giroux D, Van Meerbeeck J, Goldstraw P. The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. J Thorac Oncol. 2009;4(7):792–801.CrossRefPubMed Chansky K, Sculier JP, Crowley JJ, Giroux D, Van Meerbeeck J, Goldstraw P. The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. J Thorac Oncol. 2009;4(7):792–801.CrossRefPubMed
18.
go back to reference Takamochi K, Yoshida J, Nishimura M, Yokose T, Sasaki S, Nishiwaki Y, et al. Prognosis and histologic features of small pulmonary adenocarcinoma based on serum carcinoembryonic antigen level and computed tomographic findings. Eur J Cardiothorac Surg. 2004;25(5):877–83.CrossRefPubMed Takamochi K, Yoshida J, Nishimura M, Yokose T, Sasaki S, Nishiwaki Y, et al. Prognosis and histologic features of small pulmonary adenocarcinoma based on serum carcinoembryonic antigen level and computed tomographic findings. Eur J Cardiothorac Surg. 2004;25(5):877–83.CrossRefPubMed
19.
go back to reference Selcukbiricik F, Bilici A, Tural D, Erdamar S, Soyluk O, Buyukunal E, et al. Are high initial CEA and CA 19–9 levels associated with the presence of K-ras mutation in patients with metastatic colorectal cancer? Tumor Biol. 2013;34(4):2233–9.CrossRef Selcukbiricik F, Bilici A, Tural D, Erdamar S, Soyluk O, Buyukunal E, et al. Are high initial CEA and CA 19–9 levels associated with the presence of K-ras mutation in patients with metastatic colorectal cancer? Tumor Biol. 2013;34(4):2233–9.CrossRef
Metadata
Title
Reevaluation of survival and prognostic factors in pathologic stage I lung adenocarcinoma by the new 2009 TNM classification
Authors
Xiaohong Fan
Xueyan Zhang
Huimin Wang
Bo Jin
Publication date
01-06-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 6/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-1781-8

Other articles of this Issue 6/2014

Tumor Biology 6/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine